You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,687,454

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,687,454 protect, and when does it expire?

Patent 9,687,454 protects SUBOXONE and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 9,687,454

Patent landscape, scope, and claims:

Title:	Sublingual and buccal film compositions
Abstract:	The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
Inventor(s):	Myers; Garry L. (Kingsport, TN), Hilbert; Samuel D. (Jonesboro, TN), Boone; Bill J. (Johnson City, TN), Bogue; Beuford Arlie (Valparaiso, IN), Sanghvi; Pradeep (Valparaiso, IN), Hariharan; Madhusudan (Munster, IN)
Assignee:	Indivior UK Limited (Slough, GB)
Application Number:	14/989,669
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,687,454
Patent Claim Types: see list of patent claims	Use; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,687,454

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION	⤷ Subscribe
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION	⤷ Subscribe
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION	⤷ Subscribe
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,687,454

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	078417	⤷ Subscribe
Australia	2010279440	⤷ Subscribe
Brazil	112012002817	⤷ Subscribe
Canada	2770180	⤷ Subscribe
Chile	2012000313	⤷ Subscribe
China	102548535	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.